October 30, 2023

Methylphenidate is associated with reduced risk of all-cause mortality in youths with ADHD in a nationwide population cohort study

Youths with ADHD are at higher risk of suicide, burn injuries, road injuries, and more generally all-cause mortality than normally developing children. Methylphenidate (MPH) is known to be effective in reducing ADHD symptoms. Can it also reduce the risk of all-cause mortality? A team of Taiwanese researchers, collaborating with two British researchers, explored that question by looking at a nationwide population cohort.

Taiwan has a single-payer national health insurance system that includes the entire population (99.6 percent coverage). Using the National Health Insurance Research Database (NHIRD), the team identified over 183,000 youths under 18 with an ADHD diagnosis. Of these, just over 68,000 had been prescribed to MPH. The team matched them with an equal number of ADHD youths who were not prescribed MPH. All records were anonymized and checked against the National Mortality Register.

All-cause mortality was split into two subcategories. Unnatural-cause mortality consisted of homicide, suicide, and motor vehicle fatalities. Natural-cause mortality encompassed all other premature deaths. In the raw data, ADHD youths on MPH had half the all-cause mortality of those not on MPH. Natural-cause mortality was down about 40 percent and unnatural-cause mortality was by almost two-thirds. In the non-MPH group, 32 committed suicide in the follow-up year, versus only a single individual in the MPH group. There were seven homicide victims in the non-MPH group, versus none at all in the MPH group.

These staggering reductions, however, were almost exclusively among males. The team then adjusted for potential confounding variables - gender, age, residence, insurance premium, out-patient visits, and pre-existing diagnoses. In the adjusted model, the risk for all-cause mortality was still reduced - by about 20 percent - for those on MPH and remained statistically significant. Virtually identical reductions were found for males and for children first diagnosed with ADHD between 4 and 7 years old. But all other risk estimates became statistically non-significant, due in large measure to the rarity of mortality events.

The authors concluded, "This is the first study reporting that a longer interval between first ADHD diagnosis and first prescription of MPH is associated with a higher risk of all-cause mortality. In addition, we also found that participants receiving longer-duration MPH treatment had a lower risk of all-cause mortality. ... an implication is that receiving a diagnosis earlier and receiving medication earlier may reduce the risk of later adverse consequences."

They nevertheless cautioned, "although we adjusted for multiple covariant, information lacking in the database precluded the measurement of other possible confounders, such as family history, psychosocial stressors, the effect of behavioral therapy or severity of comorbidities. Therefore, as with all observational data, it is not possible to be conclusive about whether the association with lower mortality is related to an effect of MPH treatment itself or whether other characteristics of the children receiving MPH may account for the lower risk (i.e. confounding by indication).

Finally, although the cohort sizes were large, the number of deaths was small, and this limited statistical power, particularly for the investigation of cause-specific mortality and of subgroup differences. Because of the relatively low number of deaths and limited follow-up duration, longer-term studies with larger samples are warranted ..."

Vincent Chin-HungChen, Hsiang-Lin Chan, Shu-I Wu, Mong-Liang Lu, Michael E. Dewey, Robert Stewart, and Charles Tzu-Chi Lee, "Methylphenidate and mortality in children with the attention-deficit hyperactivity disorder: a population-based cohort study," British Journal of psychiatry (2020), https://doi.org/10.1192/bjp.2020.129.

Related posts

No items found.

Swedish Nationwide Population Study: Little ADHD Risk from Vacuum-Assisted Delivery

Vacuum-assisted delivery (VAD), also called vacuum extraction, is an assisted vaginal birth method in which a soft plastic cup is attached to the baby’s head with suction to help guide the infant through the birth canal during the pushing stage. Clinicians typically use VAD when labor stalls, the mother is exhausted, or there are concerns about the baby’s heart rate. It is an alternative to a cesarean section (C‑section) that can avoid major surgery. 

In Sweden, VAD is used in about 6%–9% of births, while forceps deliveries are uncommon. When performed with the fetal head at the outlet station (very low in the birth canal), VAD is usually quick and carries minimal risk of injury in full-term babies; these outlet procedures make up roughly half of all VADs. By contrast, several studies have linked VAD performed at mid or low fetal head stations with more serious neonatal complications, such as intracranial bleeding, seizures and, in rare cases, death. 

Despite concerns about short-term neonatal injury after mid/low VAD, research on long-term neurodevelopmental outcomes is limited. A few more recent studies have not found clear links between VAD and adverse long-term outcomes, but most of those studies did not separate outlet from mid/low procedures. 

To address this gap, the authors conducted a nationwide, population-based study in Sweden to compare neonatal and long-term neurodevelopmental outcomes after VAD, and to stratify results by fetal station. They included emergency cesarean delivery and spontaneous vaginal delivery as reference groups to help interpret outcomes after VAD. 

The study used Sweden’s linked national registers, possible because every resident has a personal identification number. Sweden’s tax-funded single-payer health system and nearly universal hospital births mean the registers provide comprehensive, standardized data suitable for long-term follow-up. 

The cohort comprised 630,985 singleton term births from 1997 through 2014. Of these, 73,215 (11.6%) were delivered by VAD, 73,739 (11.7%) by emergency cesarean delivery, and 484,031 (76.7%) by spontaneous vaginal delivery. Among the VAD births, 31,014 (42.4%) were classified as mid/low station and 42,201 (57.6%) as outlet VAD. 

The investigators adjusted their analyses for potential confounders including maternal age; early-pregnancy body-mass index; smoking during pregnancy; the child’s birth year; preeclampsia; gestational diabetes; chorioamnionitis; maternal education level; and maternal medical or psychiatric conditions (type 1 or type 2 diabetes, ADHD, autism spectrum disorder, depression and anxiety). 

After adjustment, VAD overall was associated with a 6% lower risk of later being diagnosed with ADHD compared with the reference groups. When broken down by fetal station, mid/low VAD showed no difference in ADHD risk, while outlet VAD was associated with a 9% lower risk. For comparison, spontaneous vaginal delivery was associated with a 12% lower risk of later ADHD. 

The authors concluded that, in this large nationwide cohort, the findings may offer reassuring evidence about the overall long-term neurodevelopmental safety of VAD.  

‍

‍

‍

Meta-analysis: Almost Three in Four ADHD Patients Receive Pharmaceutical Treatment

The Background:

Management of ADHD relies on both medications and non-medication approaches. Clinical guidelines often recommend medication as the first-line treatment for adults, while non-medication interventions are often preferred for children. Medicines fall into two main groups: stimulants (for example, methylphenidate and amphetamines), which have strong and well-established evidence and are generally considered first choice, and non-stimulants (such as atomoxetine), which are typically used when stimulants are contraindicated, not tolerated, or ineffective. 

How many people with ADHD receive medication is an important indicator of care quality and can be tracked at the national level. Untreated ADHD can affect many areas of life, from physical health, to school and work performance, to relationships emotional well-being. ADHD is associated with poorer quality of life, higher risk of accidents, substance use issues, criminal behavior, educational underachievement, and even increased premature mortality. The condition also places a substantial burden on families and caregivers, so understanding treatment rates matters for individuals and society. 

Most epidemiological research has measured how common diagnosed ADHD is, but the share of those diagnosed who actually receive medication can vary a lot. That variation reflects differences in how ADHD is diagnosed, how easy it is to get treatment, what clinical guidelines recommend, and cultural attitudes toward using medication. 

The Study:

This paper presents the first comprehensive meta-analysis to estimate how common pharmacological treatment is among children, adolescents, and adults with clinically confirmed ADHD. The analysis included only register-based population studies where diagnoses were confirmed by a qualified healthcare professional. Twelve studies meeting these criteria from Europe (the UK, Sweden, Denmark), Asia (Taiwan, South Korea), and North America (Canada, the United States) were used. Notably, these are all high-income areas, and thus unrepresentative of populations in lower-income countries.  

The pooled estimate showed that about 73 percent of diagnosed individuals in prosperous parts of the world with well-developed health care systems were receiving medication, but there was very high variation between studies. 

The Results:

The authors conclude there is substantial global variation in ADHD medication use. Overall, a relatively high proportion of people diagnosed with ADHD are treated with medication, which may reflect improved recognition and access to care. The large differences between studies probably reflect differing health systems, diagnostic rules, treatment definitions, study populations, and reporting practices, and they underline the need for more standardized definitions and reporting to make comparisons more meaningful.  

There is also a need for information from lower-income regions, but that is complicated by an absence of register-based population studies in countries with more limited health care access.

‍

November 4, 2026

Meta-analysis Finds Three- to Eight-fold Higher ADHD Prevalence Among Adults with Substance Use Disorders

The Background:

Because impulsivity is a core feature of ADHD, researchers have suggested it may raise the likelihood that someone will use psychoactive substances (including alcohol) and go on to develop a substance use disorder (SUD). When ADHD and SUD occur together in adolescents, treating one disorder alone usually has little or no positive effect on the other; current guidance therefore recommends treating both conditions at the same time using evidence-based approaches for each. 

Given how much ADHD can worsen outcomes for people with primary SUDs, it is important to identify ADHD in people who are being treated for substance problems. 

The Study:

A recent systematic meta-review found that, by current official criteria, ADHD affects about 7.2% of children and adolescents and about 2.6% of adults (Chaulagain et al., 2023). When adult ADHD is defined without the requirement that symptoms began by age 11, roughly 6.8% of adults meet criteria. A large body of research links ADHD to higher rates of medical problems, poorer quality of life, greater risk of suicide, more accidental injuries, worse educational outcomes, and increased involvement with the criminal justice system. 

The present study is the first meta-analysis to estimate how common clinically diagnosed ADHD is among adults (age 18+) who are in treatment for psychoactive substance use disorders, and to provide those estimates by sex and by the specific substance used. 

The authors included only studies of adults treated for a SUD (including alcohol). Eighty-four studies met the criteria, representing more than 34,000 people. Across all studies, the pooled prevalence of clinically diagnosed ADHD was 22%. 

To put that in context, 22% is about eight times higher than the 2.6% adult prevalence using the stricter official definition, and about three times higher than the 6.8% rate when the childhood-onset requirement is relaxed. By substance, the prevalence was similar for alcohol (24%) and opioids (22%), with no significant difference between males and females. Prevalence among people treated for cocaine use was somewhat lower overall (18%), driven largely by lower rates among women, for whom the rate was no higher than in the general population. Estimates were higher for people using benzodiazepines and cannabis, but those figures are based on a very small number of users (256 and 249 people, respectively) and are therefore less certain. 

The Results: 

The authors conclude: “These findings underscore the need for early identification and treatment of ADHD as most substance use disorders develop in adolescence and young adulthood. While in treatment for ADHD, appropriate screening and management of substance use is possible.” 

‍

October 29, 2026